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1.1. Need for developing case definitions and guidelines for data
collection, analysis, and presentation for chorioamnionitis as an
adverse event following immunization
Chorioamnionitis is a term encompassing a broad spectrum of
disease during pregnancy that is characterized by inflammation
and/or infection of intrauterine structures such as the placenta,
the chorion and amnion (see Fig. 1) [1,2]. The clinical presentationof chorioamnionitis can vary based on clinical, microbiologic, and
histologic factors which interact and overlap to varying degrees
[2,3]. Signs and symptoms depend on whether a primary inflam-
matory versus an infectious process is found. Placental inflamma-
tion is often clinically silent and can signal the normal
physiologic process of parturition, an inflammatory process, but
can also be a sign of sub-clinical infection. The identification of
an infectious etiology, such as a positive amniotic fluid culture,
or the development of clinical findings, are indicative of a patho-
logic process that may progress to more severe maternal and
neonatal disease. Distinction of inflammatory versus infectious eti-
ology within the spectrum of chorioamnionitis is therefore impor-
tant, given the profound differences on subsequent maternal and
neonatal morbidity. For the purposes of this case definition we will
Fig. 1. Placental anatomy in the context of intra-amniotic infections (See Sec-
tion 1.3.4c). Reprinted with permission from Goldenberg RL, Hauth JC, Andrews
WW. Intrauterine infection and preterm delivery. N Engl J Med. 2000 May 18;342
(20):1500–7 [65].
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amniotic infection, and will use these terms interchangeably
throughout the remainder of this document. Although chorioam-
nionitis may affect neonatal morbidity, we will focus on manifesta-
tions and pathology found during pregnancy.
Epidemiology, pathogenesis and risk factors
Chorioamnionitis or intra-amniotic infection complicates
around 1–5% of deliveries at term [4,5]; however, estimates can
vary based on diagnostic criteria used and risk factors [2]. For
example, chorioamnionitis can complicate up to one third of preg-
nancies with preterm labor [6]. The pathogenesis of intra-amniotic
infections is most commonly due to ascending infections into the
placenta and chorion-amnion [4,7]. Intrauterine infection can also
be transmitted via hematogenous spread as in the case of Listeria
monocytogenes, or as an iatrogenic infection via procedures for pre-
natal diagnosis or fetal therapy [4]. There are multiple studies
reporting risk factors for chorioamnionitis, which include prelabor
rupture of membranes, prolonged labor, nulliparity, internal intra-
partum fetal monitoring, multiple vaginal exams, alcohol and
tobacco use, bacterial vaginosis, colonization with group B strepto-
coccus, and colonization with Ureaplasma urealyticum (genital
mycoplasmas) and other pathogens [5,8–12].
Maternal and neonatal outcomes
Clinically, intra-amnionitic infections can cause significant
maternal, fetal and neonatal morbidity and mortality. Women with
chorioamnionitis are at higher risk for cesarean section, need for
blood transfusion, uterine atony, pelvic abscesses, postpartum
endometritis and intensive care unit (ICU) admissions [13–15].
Severe maternal sequelae of chorioamnionitis can include puer-
peral sepsis which is an important cause of global maternal mortal-
ity both in low- and high-resource settings [16,17]. Fetal and
immediate neonatal consequences of chorioamnionitis include
neonatal depression at birth, neonatal sepsis, need for mechanical
ventilation, intraventricular hemorrhage, fetal inflammatory
response syndrome (FIRS), and neonatal mortality [14,15,18]. Pre-
term neonates are at higher risk for complications than term neo-
nates [15]. With regards to long-term neonatal outcomes,chorioamnionitis is associated with bronchopulmonary dysplasia,
periventricular leukomalacia, and cerebral palsy [19,20].
Diagnosis of chorioamnionitis
The diagnosis of chorioamnionitis has been made in previous
studies by varying clinical criteria, laboratory, and histologic find-
ings. The presence of inflammation and/or microbes in the pla-
centa, amnion, chorion or amniotic fluid is considered the gold
standard for diagnosis, regardless of clinical findings [21–24].
Unfortunately, histologic examination of the placenta may not be
performed if chorioamnionitis is not suspected clinically, and, as
such, many studies of chorioamnionitis have not been able to test
the specificity of histologic chorioamnionitis. Laboratory tests,
such as amniotic fluid culture and glucose analysis, may be limited
by exclusion of amniocentesis as a diagnostic test. Even if an amni-
otic fluid culture is obtained, cultures of certain pathogens such as
Ureaplasma urealyticum are difficult to perform and not widely
available. As well, pathology services and some laboratory assess-
ments, such as microbiologic cultures, are often not readily acces-
sible in all resource settings. These challenges require that we
develop a case definition for chorioamnionitis with levels of cer-
tainty that are appropriately sensitive and specific for any clinical
setting.
Variations in the diagnostic criteria used for chorioamnionitis in
the literature make it difficult to interpret individual study results
and compare data across studies. Diagnostic criteria for clinical
chorioamnionitis are based on early work by Gibbs and colleagues
who described chorioamnionitis as maternal fever with two of the
following: maternal tachycardia, fetal tachycardia, uterine tender-
ness, foul odor of amniotic fluid, or maternal leukocytosis [25]. The
presence of multiple criteria for clinical chorioamnionitis as well as
risk factors has a higher correlation with histologic chorioamnioni-
tis, while individual clinical chorioamnionitis criteria on their own
have variable sensitivity and low specificity [2,23,26]. Subclinical
chorioamnionitis and non-infectious inflammation are within the
spectrum of chorioamnionitis described in the literature and likely
contribute to discrepancies found between clinical, culture-based
and histologic chorioamnionitis (2) [27]. Our case definition does
not include these entities.
There are a variety of definitions for chorioamnionitis set forth
by international and national health authorities. In their guideline
document, the World Health Organization (WHO) defines peripar-
tum infections as ‘‘bacterial infection of the genital tract or its sur-
rounding tissues occurring at any time between the onset of
rupture of membranes or labor and the 42nd day postpartum in
which two or more of the following are present: pelvic pain, fever,
abnormal vaginal discharge, abnormal smell/foul odor discharge or
delay in uterine involution” [28]. The WHO’s International Classifi-
cation of Diseases ICD-10 and ICD-11 define chorioamnionitis as
O41.12X ‘‘Chorioamnionitis” and as JA88.1 ‘‘Infection of the amni-
otic sac and membranes,” respectively [29,30]. The United King-
dom’s National Institute for Health and Care Excellence (NICE)
guidelines for preterm labor does not mention ‘‘chorioamnionitis”
but does describe prelabor rupture of membranes as risk factor for
‘‘intrauterine infection” [31]. The American College of Obstetricians
and Gynecologists defines chorioamnionitis as ‘‘an infection with
resultant inflammation of any combination of the amniotic fluid,
placenta, fetus, fetal membranes, or decidua” [32]. While these def-
initions describe chorioamnionitis, they provide limited guidance
regarding diagnostic criteria.
Vaccines and chorioamnionitis
With regards to vaccine research, there are several studies that
have investigated maternal immunizations and associations with
adverse pregnancy outcomes such as chorioamnionitis. A recent
systematic review by McMillan et al summarizes antenatal, birth
and infant outcomes including chorioamnionitis following
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discussion of vaccinations during pregnancy and chorioamnionitis.
In 2014, Kharbanda et al published their observational cohort
study involving 123,494 women. Chorioamnionitis was diagnosed
in 6.1% and 5.5% of women who did and did not receive the tetanus
toxoid, diptheria and acellular pertussis (Tdap) vaccine during
pregnancy, respectively, demonstrating a small, but significant dif-
ference in chorioamnionitis rates (risk ratio [RR] 1.19; 95% confi-
dence interval [CI] 1.13–1.26) [34]. In this study,
chorioamnionitis cases were identified retrospectively via ICD-9
codes. Of cases with ICD-9 codes for chorioamnionitis that were
randomly selected for chart review, 19.6% of placentas were posi-
tive for histologic chorioamnionitis, while 72.3% of placentas did
not have a histologic exam. The positive predictive value of a case
with ICD-9 code of chorioamnionitis also having ‘‘probable”
chorioamnionitis (defined as clinical signs of chorioamnionitis
with confirmatory histologic chorioamnionitis) was 0.50 (95% CI,
0.43–0.57), and, of note, 95% of women with an ICD-9 code for
chorioamnionitis also had an epidural which can be associated
with maternal fever.
In 2015, Morgan et al published their retrospective cohort study
of 7,378 women and did not find a statistically significant differ-
ence in chorioamnionitis rates between those who were and were
not vaccinated during pregnancy (odds ratio [OR] 1.51, 95% CI
0.77– 2.96) [33,35]. The study data was taken from an institutional
database of prospectively maintained pregnancy, birth and neona-
tal records and it is therefore unclear what diagnostic criteria for
chorioamnionitis were used in this study [35].
Another retrospective cohort study of 1759 women was pub-
lished by Berensen et al in 2016. They did not find statistically sig-
nificant differences in chorioamnionitis rates between those who
were and those who were not vaccinated with Tdap during preg-
nancy (adjusted OR 1.53, 95% CI 0.80–2.90). The diagnosis of
chorioamnionitis in this study was based on clinical findings only;
neither culture nor histopathologic findings were included for
diagnostic purposes [36].
Finally, in 2015, Datwani et al published their review of the Vac-
cine Adverse Event Reporting System (VAERS) database to explore
reports of chorioamnionitis after receipt of any vaccine in the Uni-
ted States between 1990 and 2014. Chorioamnionitis was found to
be present in 1% of pregnancy reports to VAERS and most cases had
at least one risk factor for chorioamnionitis [37].
The limitations of these studies include that they were all retro-
spective with risk for various biases. There is also a possibility that
these studies were underpowered which decreases the likelihood
of finding differences in chorioamnionitis outcomes between
women who were vaccinated in pregnancy and women who were
not.
Furthermore, based on these studies it is clear that hetero-
geneity of diagnostic criteria for chorioamnionitis makes it diffi-
cult to draw conclusions about whether associations between
maternal immunization with Tdap vaccine or any other recom-
mended vaccines during pregnancy and an increased risk of
chorioamnionitis actually exist. Each study used varying defini-
tions for chorioamnionitis including ICD-9 codes and clinical
symptoms. One study did not specify how chorioamnionitis was
defined. This prevents comparison of data across studies and
underscores the necessity for a harmonized definition for
chorioamnionitis in research studies. Vaccines currently routinely
recommended in pregnancy by WHO and national health author-
ities in the United Kingdom, the United States, Australia, and an
increasing number of countries include tetanus toxoid and inacti-
vated influenza vaccines. Most countries recommend acellular
pertussis routinely during pregnancy, while WHO recommendsthe acellular pertussis vaccine specifically in areas of high disease
burden [38–41].
1.2. Methods for the development of the case definition and guidelines
for data collection, analysis, and presentation for chorioamnionitis as
an adverse event following immunization
Due to the lack of a clear definition for chorioamnionitis to facil-
itate data comparability across trials and surveillance systems, and
following the process described in the GAIA overview paper [42] as
well as on the Brighton Collaboration Website, https://www.
brightoncollaboration.org/about-us/vision-and-mission.html, the
Brighton Collaboration Chorioamnionitis Working Group was
formed in 2018 and included members from clinical, academic,
public health, and industry backgrounds. The composition of the
working and reference group can be viewed at: http://www.
brightoncollaboration.org.
To guide the decision-making for the case definition and guide-
lines, a comprehensive literature search was performed by aca-
demic library services using Pubmed, Embase and Web of
Science. Due to the extensive and diverse topic of chorioamnionitis,
the search was limited from 1995 to the date that the search was
conducted in February 2018. The search terms for MEDLINE via
PubMed is shown below and was modified for Embase and Web
of Science search terminology (see Table 1).
The searches in MEDLINE, Embase, andWeb of Science yielded a
total of 9710 citations. These were exported to Endnote and 2755
duplicates were removed using the Endnote deduplication feature.
This left a total of 6955 unique citations found in all searches. The
complete strategy for each of the searches can be found in a sepa-
rate publication. Six committee members (AK, NC, CW, FV, AB, LE)
reviewed the search results for appropriateness to the topic via
both title/abstract and full text screening, resulting in 194 included
documents.
A separate search was done to identify any reports associating
chorioamnionitis with vaccinations, using MEDLINE and Embase
via the Embase.com platform. Results were limited to English
and the preceding 10 year period. The following search string
was used:
(chorioamnionitis’/exp AND ’vaccine’/exp/mj
AND
prenatal tdap immunization and risk of maternal and
newborn adverse’:ti)
OR
(’chorioamnionitis’/exp OR chorioamnionitis:ti,ab) AND
(’vaccine’/exp/mj OR vaccin*:ti OR immuniz*:ti OR
immunis*:ti)
Another 30 articles related to chorioamnionitis and vaccine were
found of which 7 were excluded due to study type. Of the search
for chorioamnionitis related to vaccinations, 23 were selected after
review.
In addition, we conducted a grey literature search identifying
latest edition text books in common usage in obstetrics and gyne-
cology and national obstetrics and gynecology guidelines: 14 doc-
uments were added to the study/documents to review. A manual
search of references was conducted for relevant and landmark
papers of which 12 studies were selected. A total of 243 studies
and documents, including information on a working definition
for chorioamnionitis, the appropriate method of diagnosis, or any
association of chorioamnionitis as a complication of vaccination,
Table 1
Chorioamnionitis MEDLINE search strategy for the literature search through the
academic library.
#1 (‘‘Chorioamnionitis”[Mesh] OR chorioamnionitis[tw] OR amnionitis[tw]
OR funisitis[tw])
#2 (Intrauterine infection[tw] OR intrauterine infections[tw] OR intra-
uterine infection[tw] OR intra-uterine infections[tw] OR uterine
infection[tw] OR uterine infections[tw] OR uterus infection[tw] OR
uterus infections[tw] OR intra-amniotic infection[tw] OR intra-amniotic
infections[tw]) AND (Pregnancy[mesh] OR pregnancy[tw] OR pregnant
[tw])
#3 (‘‘Inflammation”[Mesh] OR inflammation[tw] OR inflammations[tw])
AND (‘‘Extraembryonic Membranes”[Mesh] OR extraembryonic
membrane[tw] OR extraembryonic membranes[tw] OR embryo
membrane[tw] OR embryo membranes[tw] OR fetal membrane[tw] OR
fetal membranes[tw] OR ‘‘Amnion”[Mesh] OR amnion[tw] OR amnions
[tw] OR amniotic membrane[tw] OR amniotic membranes[tw] OR
‘‘Chorion”[Mesh] OR chorion[tw] OR chorions[tw] OR placental
membranes[tw] OR placental membrane[tw] OR placenta membrane
[tw] OR placenta membranes[tw]) AND (Pregnancy[mesh] OR
pregnancy[tw] OR pregnant[tw])
#4 #1 OR #2 OR #3
Major and Minor Criteria used in the Case Definition of Chorioamnionitis
Major criteria
Maternal fever  At least one measurement of temperature 38 degrees
Celsius
Pathology  Findings consistent with histological chorioamnionitis
based on a recognized grading system.
Microbiology  Culture of amniotic fluid or culture of placental mem-
branes between chorion and amnion positive for
bacteria
Gestational
Age
 22–0/7 weeks estimated gestational age
 Prior to complete removal of placenta and membranes
either in the third stage of labor or during procedure.
[Absence of]  Other source of systemic infection (e.g. pyelonephritis,
appendicitis, cholecystitis)
Minor criteria
Cardiovascular  Maternal tachycardia (HR > 100 bpm)
 Fetal tachycardia: Baseline > 160 bpm for 10 min or
longer, excluding accelerations, decelerations and peri-
ods of marked variability1 or, where continuous moni-
toring is not available, an FHR exceeding 160 bpm over
at least three contractions2
Genitourinary  Uterine tenderness
 Purulent fluid from the cervical os or foul smelling
amniotic fluid
Laboratory  Maternal white blood cell count  15,000 per mm3 in
the absence of antenatal corticosteroids
1 Correlates with: Ayres-de-Campos D, Spong CY, Chandraharan E, Panel FIFMEC.
FIGO consensus guidelines on intrapartum fetal monitoring: Cardiotocography. Int J
Gynaecol Obstet. 2015;131(1):13–24.
2 Correlates with: Lewis D, Downe S, Panel FIFMEC. FIGO consensus guidelines on
intrapartum fetal monitoring: Intermittent auscultation. Int J Gynaecol Obstet.
2015;131(1):9–12.
Fig. 2. Flow diagram describing pathway for source identification.
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sources is shown in Fig. 2.
1.3. Rationale for selected decisions about the case definition of
chorioamnionitis as an adverse event following immunization
1.3.1. The term chorioamnionitis
Alternative terminology for chorioamnionitis includes intra-
amniotic infection and amnionitis. In the clinical setting with pos-
itive clinical signs and symptoms, chorioamnionitis is often
referred to as ‘‘clinical chorioamnionitis” in the literature. Positive
amniotic fluid culture or an elevated amniotic fluid white blood
cell count can be referred to as microbial invasion of the amniotic
cavity (MIAC) and intraamniotic inflammation, respectively, which
are also within the spectrum of chorioamnionitis. Pathologic pla-
cental findings consistent with chorioamnionitis are usually
referred to as ‘‘histologic chorioamnionitis.” More recently the
term ‘‘triple I” was coined in 2016 by an expert panel workshop
at the Eunice Kennedy Shriver National Institute of Child Healthand Human Development (NICHD) in the United States to empha-
size the full spectrum of the disease as ‘‘intrauterine inflammation
or infection or both”, however this term is not in wide-spread use
within the United States or internationally [1].
1.3.2. Related terms of chorioamnionitis and differentiation of
chorioamnionitis from other (similar/associated) disorders
For the purposes of developing this case definition, the focus is
on the intraamniotic infectious manifestation of chorioamnionitis
that occurs during pregnancy. Related terms of chorioamnionitis
that are not included in this case definition therefore are:
– Intraamniotic inflammation
– ‘‘Triple I”
– Funisitis
– Fetal inflammatory response syndrome
– Septic abortion
– Postpartum endometritis
Intraamniotic inflammation:
 Findings of acute histologic chorioamnionitis with placental
invasion of polymorphonuclear cells but without evidence of
intraamniotic infection (i.e. negative culture or negative clinical
chorioamnionitis) [26].
‘‘Triple I”
 Term coined by the NICHD workshop expert panel to better
describe ‘‘intrauterine inflammation or infection or both” [1].
This term is not used within this case definition as it can cause
confusion, especially outside of the United States, and because
the goal of this case definition is to focus on chorioamnionitis
as an intra-amnionitic infection.
Funisitis
 Presence of polymorphonuclear cells in fetal structures includ-
ing the umbilical cord (i.e. the umbilical vessels and/or Whar-
ton’s jelly). Funisitis is the histologic counterpart to Fetal
Inflammatory Response Syndrome [27].
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 Describes a systemic inflammatory response within the fetus
stemming from microbial invasion of the fetus in utero. FIRS
correlates with histologic findings of funisitis [27]. It describes
the fetal response as opposed to the maternal response as is
seen in chorioamnionitis.
Septic abortion (add reference for Rouse C, Gravett M et al)
 Describes evidence of intrauterine infection within 42 days of a
competed abortion or a non-viable pregnancy at less than
22 weeks estimated gestational age.2
Postpartum endometritis (add reference for Rouse C, Gravett M
et al)
 Describes evidence of intrauterine infection within 42 days of a
live birth or stillbirth.
1.3.3. Formulating a case definition that reflects diagnostic certainty:
weighing specificity versus sensitivity
The focus of this Brighton Collaboration case definition is on
chorioamnionitis with three levels of diagnostic certainty. It needs
to be emphasized that the grading of definition levels for this case
definition is entirely about diagnostic certainty and does not reflect
clinical severity of an event. Thus, a clinically severe event may
appropriately be classified as Level 2 or 3 rather than Level 1 if it
could reasonably be of non-chorioamnionitis etiology. Level 1 diag-
nostic certainty typically incorporates gold standard diagnostic
methods and has the greatest specificity for an adverse event,
while Levels 2 and 3 have increasing sensitivity for a disease but
decreasing specificity. Detailed information about the severity of
the event should always be recorded, as specified by the data col-
lection guidelines. In addition, while a case may not meet the
chorioamnionitis case definition diagnostic criteria, the individual
woman may still require medical attention and should undergo a
thorough medical evaluation or be directed to the nearest health
facility.
The number of signs and/or symptoms that will be documented
for each case may vary considerably. The case definition has been
formulated such that the Level 1 definition is highly specific for
the condition. As maximum specificity normally implies a loss of
sensitivity, two additional diagnostic levels have been included
in the definition, offering a stepwise increase of sensitivity from
Level 1 down to Level 3, while retaining an acceptable level of
specificity at all levels. In this way it is hoped that all possible cases
of chorioamnionitis can be captured.1.3.4. Rationale for individual criteria or decision made related to the
case definition
Based on our literature review, factors important for the diag-
nosis of chorioamnionitis include clinical, laboratory and microbi-
ology, and pathology findings.
a. Clinical findings2 This gestational age cut-off is based on the Brighton Collaboration spontaneous
abortion and ectopic pregnancy guidelines and may not be applicable in all settings
(Source: Rouse CE, Eckert LO, Babarinsa I, Fay E, Gupta M, Harrison MS, Kawai AT,
Kharbanda EO, Kucuku M, Meller L, Mallett Moore T, Subelj M, Kochhar S, Tavares-Da-
Silva F; Global Alignment of Immunization Safety in Pregnancy (GAIA) Abortion Work
Group; Brighton Collaboration Abortion Working Group. Spontaneous abortion and
ectopic pregnancy: Case definition & guidelines for data collection, analysis, and
presentation of maternal immunization safety data. Vaccine. 2017 Dec 4;35(48Pt
A):6563–6574).Clinical findings described in published literature that are
important for the diagnosis of clinical chorioamnionitis include
maternal fever, uterine tenderness, maternal tachycardia, fetal
tachycardia, and purulent fluid coming from the cervical os.
Persistent maternal temperature 38 degrees Celsius or 100.4
degrees Fahrenheit is considered an abnormal finding during the
antepartum and intrapartum period. Elevated maternal tempera-
ture can be caused by infectious processes such as chorioamnioni-
tis but has also been found to be associated with non-infectious
etiologies including epidural anesthesia and elevated room tem-
perature [43,44]. Presence of maternal fever is a necessary criterion
for the diagnosis of clinical chorioamnionitis [45]. For the purposes
of this case definition, we will use the case definition for fever that
was previously developed by the Brighton Collaboration which
defines fever as temperature 38 degrees Celsius on one occasion
[46]. Given potentially confounding antepartum and intrapartum
factors, it is considered prudent to confirm maternal fever after
one finding of elevated temperature.
Chorioamnionitis is also highly associated with maternal tachy-
cardia with heartrate (HR) greater than 100 beats per minute and
fetal tachycardia with fetal heartrate (FHR) greater than 160 beats
per minute [2]. One study found that 20–80% of chorioamnionitis
cases had maternal tachycardia, while 40–70% had fetal tachycar-
dia [45]. There are several non-infectious causes for maternal
tachycardia such as medication side effects, hemodynamic
changes, and pain; while non-infectious causes for sustained fetal
tachycardia are less common, but can include maternal illness,
hypoexemia, tachyarrhythmia or prematurity.
Other, more subjective, criteria for chorioamnionitis include
uterine tenderness and purulent fluid coming from the cervical
os. Uterine tenderness is assessed via physical examination and
may be confounded by contraction pain or masked by epidural
anesthesia. Purulent fluid coming from the os depends on a specu-
lum examination. Uterine tenderness and purulent fluid from the
cervical os were found in 4% to 25% and 5% to 22% of chorioam-
nionitis cases, respectively [45].
Diagnosis of clinical chorioamnionitis is largely based on two
different algorithms. The Gibbs criteria for clinical chorioamnioni-
tis or intraamniotic infection includes maternal fever plus two or
more findings of maternal tachycardia, fetal tachycardia, uterine
tenderness, foul odor of the amniotic fluid, or maternal leukocyto-
sis [25]. Subsequent studies have, for the most part, used variations
of these clinical criteria. A second algorithm for clinical chorioam-
nionitis was developed during an expert panel workshop at the
NICHD in the United States. In this workshop summary, suspected
intraamniotic infection (labeled ‘‘Triple I”) was defined as maternal
fever without a clear source plus one of the following: baseline
fetal tachycardia, maternal leukocytosis in the absence of corticos-
teroids or definite purulent fluid from the cervical os. Confirmed
intraamniotic infection (or ‘‘Triple I”) was diagnosed with amnio-
centesis-proven positive gram stain, low amniotic fluid glucose
or positive amniotic fluid culture or with placental pathologic fea-
tures consistent with infection [1].
b. Laboratory findings
Maternal leukocytosis is the laboratory finding most commonly
used in the diagnosis of clinical chorioamnionitis. A white blood
cell (WBC) count of greater or equal to 15,000/mm3 has been used
as the cut-off for this criterion [1,25]. It must be considered that
maternal leukocytosis is relatively non-specific and can be induced
by several factors including antenatal corticosteroids [2]. Antenatal
corticosteroids are especially pertinent since they are often given
to patients who are also at high risk for developing chorioamnioni-
tis, such as those with preterm labor and preterm premature
Fig. 3. Definitions synthesized for chorioamnionitis based on the systematic
literature review. (Two definitions for clinical chorioamnionitis were developed
to correlate with the more specific definition for intraamniotic infection (or ‘‘Triple
I”) from the NICHD chorioamnionitis workship (Clinical definition A), and with the
more sensitive Gibbs criteria for chorioamnioitis (Clinical definition B). Please see
Section 1.3.4 for further details.)
3 ‘‘Clinical definition 1” correlates with confirmed intraamniotic infection (or
‘‘Triple I”) per the NICHD chorioamnionitis workshop (see Section 1.3.4). *As noted in
1.3.5, Clinical Definition A and B were included as separate entities given their
widespread use and historic significance.
4 This correlates with the Brighton Collaboration case definition for fever.
Confirmation of fever, however, is recommended (see Section 1.3.4).
5 This correlates with: Ayres-de-Campos D, Spong CY, Chandraharan E, Panel
FIFMEC. FIGO consensus guidelines on intrapartum fetal monitoring: Cardiotocogra-
phy. Int J Gynaecol Obstet. 2015;131(1):13–24.
6 This correlates with: Lewis D, Downe S, Panel FIFMEC. FIGO consensus guidelines
on intrapartum fetal monitoring: Intermittent auscultation. Int J Gynaecol Obstet.
2015;131(1):9–12.
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protein, interleukin-6, soluble intracellular adhesion molecule
(sICAM), procalcitonin, lipopolysaccharide binding protein (LBP)
and metalloproteinase-8 exist, however, they are of limited value
clinically and often used only in research settings [47–49].
c. Histological findings
The association between histologic findings of chorioamnionitis
in the placenta and infection is well established. Positive histologic
findings have been found to be more sensitive than clinical
chorioamnionitis confirmed via amniotic fluid culture [23,50]. In
addition, histologic chorioamnionitis in term, low-risk pregnancies
is often associated with placental inflammation rather than placen-
tal infection [26]. The diagnosis of histologic chorioamnionitis is
performed retrospectively following childbirth. The diagnostic cri-
teria are based on the stage and grade of maternal polymorphonu-
clear leukocyte invasion per high-power field into the placental
plate and into the membranes, from the chorion to the amnion
in an amniotropic direction [51] (see placental anatomy Fig. 1).
There are various staging and grading criteria that have been used
in the literature regarding pathologic findings of chorioamnionitis
within the placenta and membranes and include Redline, Salafia,
and Blanc criteria [24,52,53]. Redline criteria for diagnosis of histo-
logic chorioamnionitis are outlined in Appendix B.
d. Microbiological findings
While numerous studies have shown correlation between posi-
tive amniotic fluid culture and chorioamnionitis, positive fluid cul-
tures can also be found in subclinical infections [21]. Similarly,
positive culture results for pathogenic bacteria from swabs between
the layers of the placental membrane, the chorion and amnion, cor-
relate with intraamniotic infection [22]. Most intra-amniotic infec-
tions are ascending in origin from the genital tract and are
polymicrobial, with both anaerobic and aerobic organisms isolated.
In one study, women with acute intra-amniotic infection were
found to have higher rates of high-virulence isolates compared to
controls. These included group B streptococci, a-hemolytic strepto-
cocci, Escherichia coli, Clostridium spp, Bacteroides spp, among others
[25]. Other routes of infection described include hematogenous
spread of bacteria such as Listeria monocytogenes, group A strepto-
cocci and Campylobacter spp. The risk of iatrogenic intra-amniotic
infection from invasive fetal therapy or prenatal diagnostic proce-
dures is low if appropriate precautions are taken [4]. Other tests
on amniotic fluid, including glucose level, lactate dehydrogenase
activity, white blood cell count, and gram stain, are less reliable in
identifying and confirming chorioamnionitis [1,54]. Nucleic amplifi-
cation tests such as polymerase chain reaction (PCR) for detection of
intraamniotic infection is used mainly for research purposes [55].
Influence of treatment on fulfilment of case definition
The Working Group decided against using ‘‘antibiotic treat-
ment” or ‘‘antibiotic treatment response” towards fulfillment of
the chorioamnionitis case definition.
A treatment response or its failure is not in itself diagnostic, and
may depend on variables such as clinical status, comorbidities,
antenatal and intrapartum factors, and other clinical parameters.
This is especially pertinent in chorioamnionitis cases since while
antibiotics are typically administered to treat clinical signs and
symptoms, the ultimate treatment is evacuation of the uterus via
childbirth or termination of pregnancy.
1.3.5. Summary of clinical, laboratory, histology and microbiology
definitions used for the chorioamnionitis case definition
Based on the discussion in Section 1.3.4, currently available def-
initions (see Fig. 3) are summarized here for the purpose of devel-oping the chorioamnionitis case definition (See Fig. 3 and
Section 2).
It is important to note that Clinical Definition A and Clinical def-
inition B were included as separate entities given their widespread
use and historic significance. Neither is considered superior; how-
ever, Clinical Definition A is more specific while Clinical Definition
B is more sensitive.
Clinical Definition A3*:
Maternal fever  38 degrees Celsius on one occasion.4
Plus
One or more:
 Baseline fetal tachycardia (FHR > 160 bpm for 10 min or longer,
excluding accelerations, decelerations and periods of marked
variability5 or, where continuous monitoring is not available,
an FHR exceeding 160 bpm during and after at least three consec-
utive contractions6)
 Maternal WBC  15,000 per mm3 in the absence of
corticosteroids.
 Definite purulent fluid from the cervical os.
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Maternal fever  38 degrees Celsius on one occasion.8
Plus
2 of:
 Maternal tachycardia (HR > 100 bpm)
 Baseline fetal tachycardia (FHR > 160 bpm for 10 min or longer,
excluding accelerations, decelerations and periods of marked
variability9 or, where continuous monitoring is not available,
an FHR exceeding 160 bpm during and after at least three consec-
utive contractions10)
 Purulent fluid from the cervical os.
 Uterine tenderness.
 Maternal WBC  15,000 per mm3 in the absence of
corticosteroids.
Histologic diagnosis:
 Positive finding of invasion of maternal polymorphonuclear
leukocytes into the placental plate, the chorion and/or amnion
which meets criteria based on a widely accepted histopatho-
logic staging and grading system [such as Redline, Salafia, or
Blanc criteria [24,52,53]].
Culture criteria:
 Positive culture of amniotic fluid (via amniocentesis)
 And/or
 Positive culture of placental membranes (between chorion/
amnion)
1.3.6. Timing post immunization
Timing considerations diagnosis of chorioamnionitis are impor-
tant. Chorioamnionitis is largely distinguished from septic abortion
based on gestational age of the pregnancy. The Brighton Collabora-
tion definition for abortion is loss of pregnancy at less than or equal
to 21-6/7 weeks gestational age [56]. Diagnostic criteria of
chorioamnionitis should therefore include a gestational age greater
than or equal to 22 completed weeks. In addition, the majority of
chorioamnionitis cases occur in the context of preterm labor, pre-
labor rupture of membranes or prolonged labor at term. This ges-
tational age is based on the Brighton Collaboration spontaneous
abortion and ectopic pregnancy guidelines and may not be applica-
ble in all settings [56]. Criteria used for gestational age assessment
within this case definition (Section 2) is based on the Brighton Col-
laboration gestational age assessment algorithm [57]. Chorioam-
nionitis is diagnosed either prior to childbirth or termination of
pregnancy with removal of placenta and membranes or it is diag-
nosed retrospectively after delivery via pathology examination of
the placenta and membranes.
We postulate that a definition designed to be a suitable tool for
testing causal relationships requires ascertainment of the outcome
(e.g. chorioamnionitis) independent from the exposure (e.g. immu-
nizations). Therefore, to avoid selection bias, a restrictive time
interval from immunization to onset of chorioamnionitis should7 ‘‘Clinical definition 2” correlates with the Gibbs criteria (see Section 1.3.4). *As
noted in 1.3.5, Clinical Definition A and B were included as separate entities given
their widespread use and historic significance.
8 This correlates with the Brighton Collaboration case definition for fever.
Confirmation of fever, however, is recommended (see Section 1.3.4).
9 This correlates with: Ayres-de-Campos D, Spong CY, Chandraharan E, Panel
FIFMEC. FIGO consensus guidelines on intrapartum fetal monitoring: Cardiotocogra-
phy. Int J Gynaecol Obstet. 2015;131(1):13–24.
10 This correlates with: Lewis D, Downe S, Panel FIFMEC. FIGO consensus guidelines
on intrapartum fetal monitoring: Intermittent auscultation. Int J Gynaecol Obstet.
2015;131(1):9–12.not be an integral part of such a definition. Instead, wherever fea-
sible, details of this interval should be assessed and reported as
described in the data collection guidelines.
Further, chorioamnionitis often occurs outside the controlled
setting of a clinical trial or hospital. In some settings it may be
impossible to obtain a clear timeline of the event, particularly in
less developed or rural settings. In order to avoid selecting against
such cases, the Brighton Collaboration case definition avoids set-
ting arbitrary time frames.
1.4. Guidelines for data collection, analysis and presentation
As mentioned in the overview paper [58], the case definition is
accompanied by guidelines which are structured according to the
steps of conducting a clinical trial, i.e. data collection, analysis
and presentation. Neither case definition nor guidelines are
intended to guide or establish criteria for clinical management.
Both were developed to improve data comparability.
1.5. Periodic review
Similar to all Brighton Collaboration case definitions and guide-
lines, review of the definition with its guidelines is planned on a
regular basis (i.e. every three to five years) or more often if needed.
2. Case definition of chorioamnionitis11
Clinical definitions:
For all levels of diagnostic certainty
 Criteria refer to the factors described in Section 1.3 above. Levels of
diagnostic certainty for chorioamnionitis in Part 2 should always be
interpreted conjointly with the discussion in Section 1.3.5. See
Fig. 4.
 It is important to rule out other obvious sources of acute sys-
temic infection (i.e. pyelonephritis) prior to chorioamnionitis
diagnosis.
 GAIA gestational age level 1–2 criteria denote higher gestational
age certainty including a combination of certain last menstrual
period (LMP), first or second trimester ultrasound or first trime-
ster exam confirmation. Level 3 diagnostic certainty for gesta-
tional age has a lower accuracy compared to levels 1–2. (see
Appendix 1)
Level 1 of diagnostic certainty
1a712:
Clinical chorioamnionitis (definition A – See Section 1.3.5) with
at least one measurement of maternal temperature  38 degrees
Celsius.
PLUS
Confirmation via histopathology or culture (See Section 1.3.5)
PLUS
Gestational age  22–0/7 weeks by GAIA gestational age level 1–
2 criteria (See Annex 1)
1b:
Clinical chorioamnionitis (definition A – See Section 1.3.5) with
at least one measurement of maternal temperature  38 degrees
Celsius.
PLUS
Confirmation via histopathology or culture (See Section 1.3.5)11 An event does not meet the case definition if investigation reveals a negative
finding of a necessary criterion (necessary condition) for diagnosis. Such an event
should be rejected and classified as ‘‘Not a case of chorioamnionitis”
12 The difference between levels 1a and 1b is based on diagnostic certainty of
gestational age.
Fig. 4. Case definition for chorioamnionitis with levels 1–3 of certainty.
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Gestational age  22–0/7 weeks by any GAIA gestational age cri-
teria (Annex 1)
Level 2 of diagnostic certainty
2a:
Clinical chorioamnionitis (definition A – See Section 1.3.5) with
at least one measurement of maternal temperature  38 degrees
Celsius.
OR
Chorioamnionitis via histopathology or culture (See
Section 1.3.5)
PLUS
Gestational age  22–0/7 weeks by GAIA gestational age level
1–2 criteria (Annex 1)
2b:
Clinical chorioamnionitis (definition B – see Section 1.3.5) with
at least one measurement of maternal temperature  38 degrees
Celsius.
PLUS
Gestational age  22–0/7 weeks by GAIA gestational age level 1–
2 criteria (Annex 1)
2c:
Clinical chorioamnionitis (definition A or B – See Section 1.3.5)
with at least one measurement of maternal temperature  38
degrees Celsius.
OR
Chorioamnionitis via histopathology or culture (See
Section 1.3.5)
PLUS
Gestational age  22–0/7 weeks by any GAIA gestational age cri-
teria (Annex 1)
Level 3 of diagnostic certainty
3a:
Clinical chorioamnionitis (definition A or B – See Section 1.3.5)
with report of fever or maternal feeling of ‘‘feverishness.”
PLUS
Gestational age  22–0/7 weeks by any GAIA gestational age
criteria (Annex 1)
3b:Clinical chorioamnionitis (definition B – See Section 1.3.5) with-
out fever (documented or reported)
PLUS
Gestational age  22–0/7 weeks by any GAIA gestational age
criteria (Annex 1)
Major and Minor Criteria used in the Case Definition of
Chorioamnionitis3. Guidelines for data collection, analysis and presentation of
chorioamnionitis
It was the consensus of the Brighton Collaboration Chorioam-
nionitis Working Group to recommend the following guidelines to
enable meaningful and standardized collection, analysis, and pre-
sentation of information about chorioamnionitis. However, imple-
mentation of all guidelines might not be possible in all settings.
The availability of information may vary depending upon
resources, geographical region, and whether the source of informa-
tion is a prospective clinical trial, a post-marketing surveillance or
epidemiological study, or an individual report of chorioamnionitis.
Also, as explained in more detail in the overview paper in this vol-
ume, these guidelines have been developed by this working group
for guidance only and are not to be considered a mandatory
requirement for data collection, analysis, or presentation.3.1. Data collection
These guidelines represent a desirable standard for the collec-
tion of data on availability following immunization to allow for
comparability of data and are recommended as an addition to data
collected for the specific study question and setting. The guidelines
are not intended to guide the primary reporting of chorioamnioni-
tis to a surveillance system or study monitor. Investigators devel-
oping a data collection tool based on these data collection
guidelines also need to refer to the criteria in the case definition
(see above), which are not repeated in these guidelines.
Guidelines 1–44 below have been developed to address data ele-
ments for the collection of adverse event information as specified in
14 The date and/or time of onset is defined as the time post immunization, when the
first sign or symptom indicative for chorioamnionitis occurred. This may only be
possible to determine in retrospect, especially since onset signs and symptoms of
chorioamnionitis can initially be subtle in nature.
15 The date and/or time of first observation of the first sign or symptom indicative
for chorioamnionitis can be used if date/time of onset is not known.
16 The date of diagnosis of an episode is the day post immunization when the event
met the case definition at any level.
17 The end of an episode is defined as the time the event no longer meets the case
definition at the lowest level of the definition (i.e. at the time of childbirth or
termination of pregnancy and removal of placenta and membranes via the third stage
of labor or procedure).
18 E.g. recovery to pre-immunization health status, spontaneous resolution, thera-
peutic intervention, persistence of the event, sequelae, death.
19 An AEFI is defined as serious by international standards if it meets one or more of
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Harmonization (ICH) of Technical Requirements for Registration of
Pharmaceuticals for Human Use [59], and the form for reporting of
drug adverse events by the Council for International Organizations
of Medical Sciences (CIOMS) [60]. These data elements include an
identifiable reporter and patient, one or more prior immunizations,
and a detailed description of the adverse event, in this case, of
chorioamnionitis following immunization. The additional guideli-
nes have been developed as guidance for the collection of additional
information to allow for a more comprehensive understanding of
chorioamnionitis following immunization.
3.1.1. Source of information/reporter
For all cases and/or all study participants (including the preg-
nant woman and/or neonate, as appropriate), the following infor-
mation should be recorded:
(1) Date of report.
(2) Name and contact information of person reporting13 and/or
diagnosing chorioamnionitis as specified by country-specific
data protection law.
(3) Name and contact information of the investigator responsi-
ble for the subject, as applicable.
(4) Relation to the patient (e.g., immunizer [clinician, nurse],
family member [indicate relationship], other).
3.1.2. Vaccinee/Control
3.1.2.1. Demographics. For all cases and/or all study participants, as
appropriate, the following information should be recorded:
(5) Case/study participant identifiers (e.g. first name initial fol-
lowed by last name initial) or code (or in accordance with
country-specific data protection laws).
(6) Date of birth, age, and sex.
(7) For infants: Gestational age and birth weight.
3.1.2.2. Clinical and maternal immunization history. For all cases
and/or all study participants, as appropriate, the following infor-
mation should be recorded:
(8) Past medical and obstetric history, including hospitaliza-
tions, underlying diseases/disorders, infections during preg-
nancy, pre-immunization signs and symptoms including
identification of indicators for, or the absence of, a history
of allergy to vaccines, vaccine components or medications;
food allergy; allergic rhinitis; eczema; asthma.
(9) Any medication history (other than treatment for the event
described) prior to, during, and after immunization including
prescription andnon-prescriptionmedication aswell asmed-
ication or treatment with long half-life or long-term effect.
(e.g. immunoglobulins, blood transfusion and immunosup-
pressants such as steroids given to accelerate lung maturity).
(10) Immunization history (i.e. previous immunizations and any
adverse event following immunization (AEFI)), in particular
occurrence of chorioamnionitis after a previous immuniza-
tion in pregnancy.
(11) Pregnancy history (i.e. history of or recent preterm labor, pre-
term premature rupture of membranes, need for cervical cer-
clage placement or other obstetric procedures), in particular
any condition that would increase the risk of chorioamnioni-
tis regardless of whether immunization in pregnancy occurs.13 If the reporting center is different from the vaccinating center, appropriate and
timely communication of the adverse event should occur.3.1.3. Details of the maternal immunization
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(12) Date, time and place (city/region) of immunization(s).
(13) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL, 0.5 mL, etc) and number of dose
if part of a series of immunizations against the same
disease).
(14) The anatomical sites (including left or right side) of all
immunizations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(15) Route and method of administration (e.g. intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(16) Needle length and gauge.
3.1.4. The adverse event
(17) For all cases at any level of diagnostic certainty and for
reported events with insufficient evidence, the criteria ful-
filled to meet the case definition should be recorded.
Specifically, document:
(18) Clinical description of signs and symptoms of chorioam-
nionitis, and if there was medical confirmation of the event
(i.e. patient seen by physician or skilled birth attendant).
(19) Date/time of onset14, first observation15 and diagnosis16, end
of episode17 (i.e. time of delivery or termination of pregnancy)
and final outcome18 (i.e. development of postpartum
endometritis or sepsis, need for further procedures such as
hysterectomy, or neonatal outcomes).
(20) Concurrent signs, symptoms, and diseases.
(21) Measurement/testingthe foll
inpatien
results
birth de Values and units of routinely measured parameters (e.g.
temperature, blood pressure) – in particular those indi-
cating the severity of the event;
 Method of measurement (e.g. type of thermometer, oral
or other route, duration of measurement, etc.);
 Results of laboratory examinations, surgical and/or
pathological findings and diagnoses if present.(22) Treatment given for chorioamnionitis, especially specify
what antibiotics and additional medications were adminis-
tered and at what dosing.
(23) Outcome (see Footnote 17) at last observation.
(24) Objective clinical evidence supporting classification of the
event as ‘‘serious”19.owing criteria: (1) it results in death, (2) is life-threatening, (3) it requires
t hospitalization or results in prolongation of existing hospitalization, (4)
in persistent or significant disability/incapacity, (5) is a congenital anomaly/
fect, (6) is a medically important event or reaction.
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immunization (e.g. food, environmental, alternative therapies
or tonics) consideredpotentially relevant to the reported event.
3.1.5. Miscellaneous/ general
(26) The duration of surveillance for chorioamnionitis should be
predefined based on20 To d
reporte
certaint
definitio
diagnos
approac
given e
requirem
should
the eve Biologic characteristics of the vaccine e.g. live attenuated
versus inactivated component vaccines;
 Biologic characteristics of the vaccine-targeted disease;
 Biologic characteristics of chorioamnionitis including
patterns identified in previous trials (e.g. early-phase tri-
als); and
 Biologic characteristics of the vaccine (e.g. nutrition,
underlying disease like immunosuppressive illness).(27) The duration of follow-up reported during the surveillance
period should be predefined likewise. It should aim to con-
tinue to resolution of the event (delivery and the postpartum
period).
(28) Methods of data collection should be consistent within and
between study groups, if applicable.
(29) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1 to 25.
(30) Investigators of patients with chorioamnionitis should pro-
vide guidance to reporters to optimize the quality and com-
pleteness of information provided.
(31) Reports of chorioamnionitis should be collected throughout
the study period regardless of the time elapsed between
maternal immunization and the adverse event. If this is
not feasible due to the study design, the study periods dur-
ing which safety data are being collected should be clearly
defined. However, since chorioamnionitis is immediately
followed by delivery or termination of pregnancy, study pro-
tocols should make every effort to follow patients until
delivery/procedure and through the postpartum or postop-
erative period in order to capture all chorioamnionitis cases
and possible infectious disease sequelae.
3.2. Data analysis
The following guidelines represent a desirable standard for
analysis of data on chorioamnionitis to allow for comparability of
data and are recommended as an addition to data analyzed for
the specific study question and setting.
(32) Reported events should be classified in one of the following
five categories including the three levels of diagnostic cer-
tainty. Events that meet the case definition should be classi-
fied according to the levels of diagnostic certainty as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional cat-
egories for analysis.
Event classification in 5 categories20etermine the appropriate category, the user should first establish, whether a
d event meets the criteria for the lowest applicable level of diagnostic
y, e.g. Level three. If the lowest applicable level of diagnostic certainty of the
n is met, and there is evidence that the criteria of the next higher level of
tic certainty are met, the event should be classified in the next category. This
h should be continued until the highest level of diagnostic certainty for a
vent could be determined. Major criteria can be used to satisfy the
ent of minor criteria. If the lowest level of the case definition is not met, it
be ruled out that any of the higher levels of diagnostic certainty are met and
nt should be classified in additional categories four or five.Event meets case definition
(1) Level 1: Criteria as specified in the chorioamnionitis case
definition
(2) Level 2: Criteria as specified in the chorioamnionitis case
definition
(3) Level 3: Criteria as specified in the chorioamnionitis case
definition
Event does not meet case definition
Additional categories for analysis
(4) Reported chorioamnionitis with insufficient evidence to
meet the case definition21
(5) Not a case of chorioamnionitis22
(33) The interval between maternal immunization and reported
chorioamnionitis could be defined as the date/time of
immunization during pregnancy to the date/time of onset
(See Footnote 13) of the first symptoms and/or signs consis-
tent with the definition. The time-dependent nature of
exposure to vaccination within pregnancy, time-dependent
increased risk of events as pregnancy progresses and poten-
tial bias such as variable opportunity for vaccination in
pregnancy must be considered [61]. If few cases are
reported, the concrete time course could be analyzed for
each. Examples of increments that could be used for data
analysis are as follows:
Subjects with Chorioamnionitis by Interval to Presentation21
m
in
22
fin
shInterval*If the evidence available for an event is insufficient because
issing, such an event should be categorized as ‘‘Reported chorioam
sufficient evidence to meet the case definition”.
An event does not meet the case definition if investigation reve
ding of a necessary criterion (necessary condition) for diagnosis.
ould be rejected and classified as ‘‘Not a case of chorioamnionitis”.Number<72 h after immunization
72 - <7 days after immunization
1 week - <4 weeks after immunization
4 week increments thereafter until delivery or
termination of pregnancy with removal of
placenta and membranes either by completion of
the third stage of labor or by procedure.Total(34) The occurrence of a possible chorioamnionitis case could be
analyzed as the interval between the date/time of onset (See
Footnote 12) of the first symptoms and/or signs consistent
with the definition and the end of episode (See Footnote
16) and/or final outcome (see Footnote 17). Whatever start
and ending are used, they should be used consistently
within and across study groups. In the case of chorioam-
nionitis the end of episode may include childbirth or termi-
nation of pregnancy with removal of placenta and
membranes either during the third stage of labor or via pro-
cedure. It must be noted that histologic or culture-positive
chorioamnionitis is often diagnosed retrospectively after
childbirth or termination of pregnancy has already occurred.information is
nionitis with
als a negative
Such an event
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taken and recorded, the value corresponding to the greatest
magnitude of the adverse experience could be used as the
basis for analysis. Analysis may also include other character-
istics like qualitative patterns of criteria defining the event.
(36) The distribution of data (as numerator and denominator
data) could be analyzed in predefined increments (e.g. mea-
sured values, times), where applicable. Increments specified
above should be used. When only a small number of cases is
presented, the respective values or time course can be pre-
sented individually.
(37) Data on chorioamnionitis obtained from subjects receiving a
vaccine should be compared with those obtained from an
appropriately selected and documented control group(s) to
assess background rates in non-exposed populations
3.3. Data presentation
These guidelines represent a desirable standard for the presen-
tation and publication of data on chorioamnionitis following
immunization to allow for comparability of data and are recom-
mended as an addition to data presented for the specific study
question and setting. Additionally, it is recommended to refer to
existing general guidelines for the presentation and publication
of randomized controlled trials, systematic reviews, and meta-
analyses of observational studies in epidemiology (e.g. statements
of Consolidated Standards of Reporting Trials (CONSORT), of
Improving the quality of reports of meta-analyses of randomized
controlled trials (QUORUM), and of Meta-analysis Of Observational
Studies in Epidemiology (MOOSE), respectively) [62–64].
(38) All reported events of chorioamnionitis should be presented
according to the categories listed in guideline 32.
(39) Data on possible chorioamnionitis events should be pre-
sented in accordance with data collection guidelines 1–25
and data analysis guidelines 32–37.
(40) Terms to describe chorioamnionitis such as ‘‘low-grade”,
‘‘mild”, ‘‘moderate”, ‘‘high”, ‘‘severe” or ‘‘significant” are
highly subjective, prone to wide interpretation, and should
be avoided, unless clearly defined.
(41) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunization safety surveillance systems denomina-
tor data are usually not readily available, attempts should be made
to identify approximate denominators. The source of the denomi-
nator data should be reported and calculations of estimates be
described (e.g. manufacturer data like total doses distributed,
reporting through Ministry of Health, coverage/population-based
data, etc.).
(42) The incidence of cases in the study population should be
presented and clearly identified as such in the text.
(43) If the distribution of data is skewed, median and range are
usually the more appropriate statistical descriptors than a
mean. However, the mean and standard deviation should
also be provided.
(44) Any publication of data on chorioamnionitis should include
a detailed description of the methods used for data collec-
tion and analysis as possible. It is essential to specify:23 Use of this document should preferably be referenced by referring to the
respective link on the Brighton Collaboration website (http://www.brightoncollabo- The study design;
 The method, frequency and duration of monitoring for
chorioamnionitis;
 The trial profile, indicating participant flow during a
study including drop-outs and withdrawals to indicate
the size and nature of the respective groups under
investigation;ration.o The type of surveillance (e.g. passive or active
surveillance);
 The characteristics of the surveillance system (e.g. popu-
lation served, mode of report solicitation);
 The search strategy in surveillance databases;
 Comparison group(s), if used for analysis;
 The instrument of data collection (e.g. standardized ques-
tionnaire, diary card, report form);
 Whether the day of immunization was considered ‘‘day
one” or ‘‘day zero” in the analysis;
 Whether the date of onset (see footnote 13) and/or the
date of first observation (see footnote 14) and/or the date
of diagnosis (see footnote 15) was used for analysis; and
 Use of this case definition for chorioamnionitis, in the
abstract or methods section of a publication23.Disclaimer
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